Screen for child anxiety related disorders

Cingulate to Host CNS Key Opinion Leader Panel in New York City

Retrieved on: 
화요일, 10월 17, 2023
ADHD, Champions League, Precision Time Protocol Industry Profile, Patient, Associate, Psychiatry, Union League Club, Screen for child anxiety related disorders, Cingulata, Behavioral medicine, CNS, Central nervous system disease, Nightclub

The live-streamed event will be held from 10:00am-11:30am EST at the Union League Club in Midtown Manhattan, and will focus on the Company’s leading, late-stage asset CTx-1301(dexmethylphenidate), along with ADHD and anxiety-related disorders.

Key Points: 
  • The live-streamed event will be held from 10:00am-11:30am EST at the Union League Club in Midtown Manhattan, and will focus on the Company’s leading, late-stage asset CTx-1301(dexmethylphenidate), along with ADHD and anxiety-related disorders.
  • For those in the New York area who would like to attend, there will be space for approximately 25-30 guests in the club’s Grant Room.
  • Those who wish to watch the event virtually may do so through the link provided here , with the passcode 429018.
  • “The Cingulate team thanks Dr. Childress and Dr. Mattingly for their participation in this event.

Anxiety Treatment Without Medication Launched by Soft Reboot Wellness, Palo Alto

Retrieved on: 
목요일, 6월 15, 2023
Soft reboot, Anxiety, DSM-IV codes, Suicide, Quality of life, SGB, Neck, Screen for child anxiety related disorders, Interest, Mountain View, Mood disorder, Patient, Physician, Risk, Social isolation, Research, Mental health, News, PTSD, Pharmaceutical industry, Nursing

Sara Herman MD, founder of Soft Reboot Wellness (+1 650-419-3330), a holistic therapy center near Palo Alto, has launched an updated service for the treatment of anxiety symptoms and other mood disorders with Stellate Ganglion Block.

Key Points: 
  • Menlo Park, California--(Newsfile Corp. - June 15, 2023) - Sara Herman MD, founder of Soft Reboot Wellness (+1 650-419-3330), a holistic therapy center near Palo Alto, has launched an updated service for the treatment of anxiety and other mood disorders.
  • Anxiety Treatment Without Medication Launched By Soft Reboot Wellness, Palo Alto
    To view an enhanced version of this graphic, please visit:
    Anxiety is a condition that affects millions of people worldwide, impacting their mental health and overall quality of life.
  • The good news is that there is a new treatment option that provides relief to individuals suffering from anxiety: Stellate Ganglion Block.
  • Soft Reboot Wellness is run by Dr. Sara Herman, who has been serving Bay Area cities including Menlo Park, Palo Alto, Mountain View, and Los Altos for over 12 years.

Need a mental health day but worried about admitting it? You're not alone

Retrieved on: 
월요일, 6월 12, 2023
People, McCann, Depression, Mental disorder, Leadership, Workplace, Anxiety, Electricity, Research, National Mental Health Commission, Mental, Screen for child anxiety related disorders, Population, Time, Social isolation, World, Mental health, Nursing, Pharmaceutical industry, Management

Should you take a day off for your mental health?

Key Points: 
  • Should you take a day off for your mental health?
  • If you work for an organisation or in a team where you feel safe to discuss mental health challenges, you are fortunate.
  • Mental health challenges come in different forms.
  • But declining mental health is a longer-term trend, and it’s likely work demands have also played a role.

Managerial attitudes changing slowly

    • These attitudes make it even harder for those with diagnosed mental health disorders to find meaningful work and progress in their careers.
    • The best most recent study of managerial understanding of mental health issues dates from 2014.
    • It found only about one in ten human resource professionals and managers felt very confident in supporting employees with mental health challenges.

Framing the conversation

    • For all organisations, cultural change can start with leaders and managers speaking more openly about their own mental health challenges.
    • Such framing can help others to regard a mental health day as something that may be needed by anybody, not something for some who is “sick”.
    • Lena Wang previously received funding from National Mental Health Commission and Queensland Mental Health Commission.
    • Louise Byrne has previously received funding from the National Mental Health Commission and the Queensland Mental Health Commission.

Newly Created Free Resource on Childhood Anxiety Helps Pediatric Primary Care Providers and Parents

Retrieved on: 
화요일, 3월 14, 2023
Research, Disorder, Caregiver, Parent, Anxiety and Depression Association of America, Anxiety, MD, Education, Depression, USPSTF, Psychology, Screen, Science, Pediatrics, International Association for Child and Adolescent Psychiatry and Allied Professions, Screen for child anxiety related disorders, ADAA, Friends, PCP, Child, Mental health, PPP, Diagnosis, CDC, Anxiety disorder, Ageing, SCARED, REACH, Nursing

In October 2022, the U.S. Preventative Services Task Force (USPSTF) finalized guidelines recommending that primary care providers (PCPs) screen all children aged 8 to 18 for anxiety disorders.

Key Points: 
  • In October 2022, the U.S. Preventative Services Task Force (USPSTF) finalized guidelines recommending that primary care providers (PCPs) screen all children aged 8 to 18 for anxiety disorders.
  • This new FREE evidence-based resource, created by The REACH Institute and ADAA, can be an extremely useful tool to help primary care providers and parents during a diagnosis and treatment discussion.
  • “We are thrilled to join ADAA in providing this free resource for parents,” said REACH CEO, Dr. Lisa Hunter Romanelli.
  • REACH’s flagship course, Patient-Centered Mental Health in Pediatric Primary Care (PPP), has trained nearly 6,000 pediatric PCPs to date.

Cingulate Presents Data for Its Triple-Release Buspirone Product Candidate: CTx-2103

Retrieved on: 
월요일, 9월 19, 2022
People, Securities Exchange Act of 1934, Half-life, Tablet, Gastrointestinal tract, Safety, Precision Time Protocol, Lists of diseases, COVID-19, Risk, Gallup's List of Most Widely Admired People of the 20th Century, EBL, Cingulate cortex, Drug Quality and Security Act, Nature, Company, Nuclear medicine, Securities Act of 1933, ADHD, Anxiety disorder, U.S. Securities and Exchange Commission, Patient, Mental health, Potential, CEO, Technology, Benzodiazepine, Disorder, Barbiturate, Annual report, Anxiety, Diagnosis, NASDAQ, Solubility, Security (finance), Pharmacokinetics, GLOBE, SEC, Congress, Fear, Screen for child anxiety related disorders, Pharmaceutical industry, Generic drug, Medicine, Buspirone

KANSAS CITY, Kan., Sept. 19, 2022 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced findings from its formulation study for CTx-2103, the Company’s asset for the management of anxiety-related disorders. The data was featured in a poster presentation at the 2022 Psych Congress meeting, taking place September 17-20 in New Orleans, LA.

Key Points: 
  • The data was featured in a poster presentation at the 2022 Psych Congress meeting, taking place September 17-20 in New Orleans, LA.
  • The readout of the data is a crucial step in our quest to bring the best-possible, once-daily formulation of buspirone to patients, said ShaneJ.
  • In the study, the pharmacokinetics were evaluated for three multi-layered, timed-release oral tablets and one immediate release dose of buspirone.
  • Cingulate is developing ADHD and anxiety disorder product candidates capable of achieving true once-daily dosing using the Companys innovative PTR drug delivery platform technology.

Artelo Biosciences Reports Positive Pre-Clinical Results with its Novel Inhibitor to Fatty Acid Binding Protein 5

Retrieved on: 
화요일, 8월 16, 2022
Cortex, U.S. Securities and Exchange Commission, Securities Act of 1933, University, Cerebral cortex, Inflammation, Industry, Stony Brook University, GLOBE, Peripheral neuropathy, Cancer, Brain, Fear, Securities Exchange Act of 1934, Purging disorder, Security (finance), Research, Pain, Post-traumatic stress disorder, FABP5, Doctor of Philosophy, Lipid, Twitter, Cannabinoid, CB2, Anxiety, Nature, Neuroscience, Lead, FABP, Protein, Private Securities Litigation Reform Act, Screen for child anxiety related disorders, Diathesis–stress model, Nasdaq, PTSD, Organic acid, Pharmaceutical industry

President and Chief Executive Officer of Artelo Biosciences.

Key Points: 
  • President and Chief Executive Officer of Artelo Biosciences.
  • This new data further supports the development of our FABP inhibitor platform in anxiety-related disorders such as post-traumatic stress disorder.
  • We are encouraged by these findings which indicate inhibiting FABPs represents a promising neurobiological approach for the development of novel anxiety-inhibiting pharmacotherapies.
  • Artelo Biosciences, Inc. is a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, and neurological conditions.

Cingulate Announces Completion of CTx-2103 Human Formulation Study for the Treatment of Anxiety Disorders

Retrieved on: 
목요일, 6월 23, 2022
People, Anxiety, Half-life, Vital signs, Security (finance), Buspirone, Securities Exchange Act of 1934, COVID-19, Fear, Annual report, Technology, Precision Time Protocol, Cingulate cortex, Blood pressure, CEO, Barbiturate, Benzodiazepine, Company, U.S. Securities and Exchange Commission, Absorption, Securities Act of 1933, Risk, Mental health, Failure, Drug Quality and Security Act, NASDAQ, Anxiety disorder, Screen for child anxiety related disorders, SEC, Safety, Nature, ADHD, Patient, United Kingdom, EBL, Diagnosis, ECG, Disorder, U.S. 1 (comics), GLOBE, Pharmaceutical industry, Medicine, Generic drug

Dosing frequency is an important component of medication adherence in patients and a key contributor to treatment success or failure.

Key Points: 
  • Dosing frequency is an important component of medication adherence in patients and a key contributor to treatment success or failure.
  • Buspirone, an azapirone derivative and a 5-HT1A partial agonist, was the first non-benzodiazepine anxiolytic introduced for the treatment of generalized anxiety disorder.
  • The first human subject study of CTx-2103 was a single-center, open-label, four-arm crossover study in 12 healthy subjects.
  • Secondary objectives of the study will compare the pharmacokinetic performance of the time delayed buspirone products with a commercially available formulation.

VistaGen Announces Completion of PALISADE-1 Phase 3 Clinical Study of PH94B for the Acute Treatment of Social Anxiety Disorder

Retrieved on: 
수요일, 6월 22, 2022
Biotechnology, Mental Health, Health, Pharmaceutical, Clinical Trials, CNS, Industry, FDA, NDA, Social anxiety disorder, Therapy, Risk, COVID-19, Fear, PH94B, Safety, Neuron, Anxiety, Annual report, Subjective units of distress scale, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Panic disorder, Central nervous system disease, Benzodiazepine, Company, Brain, SUDS, U.S. Securities and Exchange Commission, Depression, Trial of the century, Fast Track, PTSD, PH10, Central nervous system, Post-traumatic stress disorder, Marketing, PALISADE, Quality of life, SAD, Screen for child anxiety related disorders, SEC, Nasdaq, MOA, Adult, Food, Patient, Employment, Principal, Pharmaceutical industry

VistaGens PALISADE-1 Phase 3 clinical trial is a U.S. multi-center, randomized, double-blind, placebo-controlled, parallel design, clinical study in adults diagnosed with SAD.

Key Points: 
  • VistaGens PALISADE-1 Phase 3 clinical trial is a U.S. multi-center, randomized, double-blind, placebo-controlled, parallel design, clinical study in adults diagnosed with SAD.
  • VistaGens PALISADE Phase 3 Program in social anxiety disorder (SAD) is designed to further demonstrate the potential of PH94B as a fast-acting, acute treatment of anxiety in adults with SAD.
  • Based on positive Phase 2 data in social anxiety disorder (SAD) patients, VistaGen is currently evaluating PH94B in two Phase 3 clinical studies in the U.S., PALISADE-1 and PALISADE-2, for the acute treatment of anxiety in adults with SAD.
  • Should ongoing Phase 3 studies be successful, PH94B has the potential to be the first FDA-approved, fast-acting, acute treatment of anxiety for adults with social anxiety disorder.

Cerevel Therapeutics Reports First Quarter 2022 Financial Results and Business Updates

Retrieved on: 
화요일, 5월 10, 2022
COVID-19, Epilepsy, PSL, Forward-looking statement, Brain, Seizure, PANSS, AES, GLOBE, American Academy of Neurology, Lists of Palestinian rocket attacks on Israel, Biotechnology, Schizophrenia International Research Society, Research, Diazepam, Schizophrenia, AAN, Positive and Negative Syndrome Scale, D1, Patient, Patient safety, Pharmacology, Clinical trial, FDA, Conference call, L-DOPA, Anxiety, Total, PAM, SIRS, Marketing, EEG, Screen for child anxiety related disorders, Intention, Congress, GABAA, American Academy, Conference, SEC, ID, Solution, G&A, Terminology, Growth, Positive, Dopamine, Therapy, Pharmaceutical industry, Online gambling, Medical imaging, Residential care, Copper

CAMBRIDGE, Mass., May 10, 2022 (GLOBE NEWSWIRE) -- Cerevel Therapeutics, (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today reported financial results for the quarter ended March 31, 2022 and provided key pipeline and business updates.

Key Points: 
  • ET
    CAMBRIDGE, Mass., May 10, 2022 (GLOBE NEWSWIRE) -- Cerevel Therapeutics , (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today reported financial results for the quarter ended March 31, 2022 and provided key pipeline and business updates.
  • Cerevel recently presented Phase 1b emraclidine data at the 2022 Congress of the Schizophrenia International Research Society (SIRS), which took place on April 6-10, 2022.
  • In February 2022, Cerevel announced positive topline results for its Phase 1 trial of darigabat in acute anxiety.
  • ET to discuss its first quarter 2022 financial results and pipeline updates.

Cerevel Therapeutics Provides Update on Pipeline Progress along with Fourth Quarter and Full Year 2021 Financial Results

Retrieved on: 
화요일, 3월 1, 2022
GLOBE, Pharmacology, Patient safety, D, Schizophrenia, PANSS, Growth, PAM, ID, Research, GABAA, COVID-19, Therapy, Company, Clinical trial, Positive, Epilepsy, Exercise, Lists of Palestinian rocket attacks on Israel, Terminology, Positive and Negative Syndrome Scale, Biotechnology, Brain, Intention, FDA, Anxiety, EST, Forward-looking statement, Patient, PSL, Screen for child anxiety related disorders, AES, Â, SEC, Medical imaging, Pharmaceutical industry, Residential care, Copper, Lithium, G&A

CAMBRIDGE, Mass., March 01, 2022 (GLOBE NEWSWIRE) -- Cerevel Therapeutics, (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today reported financial results for the fourth quarter and full year ended December 31, 2021 and provided key business updates.

Key Points: 
  • In June 2021, Cerevel announced positive topline data for its Phase 1b trial of emraclidine in people with schizophrenia.
  • In February 2022, Cerevel announced positive topline results for its Phase 1 trial of darigabat in acute anxiety.
  • In the second quarter of 2021, Cerevel received Fast Track Designation from the FDA for the development of CVL-871 in dementia-related apathy.
  • Cerevel will host a conference call and webcast today, March 1, at 8:00 a.m. EST to discuss its fourth quarter and full year 2021 financial results and pipeline updates.